Latest Regulatory News

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

Cardiex Limited has confirmed to the ASX that it holds no undisclosed information explaining the recent spike in its share price, affirming full compliance with continuous disclosure rules.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

EV Resources Limited has responded to ASX inquiries confirming the material impact of China's molybdenum export controls and recent high-grade antimony assay results on its securities.

Acorn Capital Investment Fund’s shares were suspended following a late submission of its January 2025 Net Tangible Asset Statement, attributed to human error. The company has assured shareholders the issue is resolved and trading resumed promptly.

Kina Securities confirms its 2024 underlying profit guidance amid a non-cash statutory profit reduction driven by deferred tax asset adjustments and a customer fraud impact.

Future Metals NL has addressed an ASX price query by confirming the release of drilling results from its Eileen Bore Prospect, attributing recent trading activity to investor anticipation and compliance with disclosure rules.

The Star Entertainment Group has received a $650 million debt refinancing proposal from Oaktree Capital Management, offering a potential boost to its liquidity but shadowed by significant conditions and uncertainty.

Winsome Resources has raised approximately A$7.8 million through a placement to advance its flagship Adina Lithium Project and extend the Renard Option to August 2025, with plans for an additional share purchase plan targeting A$2.5 million.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.